Description

Ionis Pharmaceuticals’ $3 Billion TRYNGOLZA Opportunity: Can The Launch Deliver?

Ionis Pharmaceuticals reported its second quarter and first half of 2026 financial results highlighting both commercial progress and pipeline developments amid ongoing investments in research and development. The company is actively launching and commercializing multiple medicines while advancing a robust pipeline in neurology and cardiometabolic diseases. A key milestone was achieved with the FDA approval of TRYNGOLZA (volanesorsen) for the reduction of triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (sHTG). TRYNGOLZA’s launch is noted to have started strongly, receiving prescriptions on its day of approval with both 50 mg and 80 mg doses quickly available. Early demand is growing among cardiologists, endocrinologists, lipidologists, and primary care physicians treating the estimated 3 million U.S. patients with sHTG, including a high-risk subset with triglycerides above 880 mg/dL or histories of pancreatitis.